“At Aptar Digital Health, we are committed to leveraging cutting-edge technology to enhance the patient experience,” said Sai Shankar, President of Aptar Digital Health. “The collaboration with Tasso to offer their technologies is a further step towards simplifying the patient journey.”
The Tasso blood collection devices will be available to patients included in Aptar Digital Health randomized-clinical trials and real-world studies, as well as to life science companies with whom Aptar Digital Health collaborates to develop digital health solutions, such as digital therapeutics, disease management platforms and digital PSPs.
Patients will have access to the Tasso+ and Tasso-M20 devices. The Tasso+ is a U.S. Food and Drug Administration (FDA) Class II 510(k)-cleared blood lancet that collects liquid whole blood samples, and the Tasso-M20, which is CE-marked, collects volumetrically-controlled dried whole blood samples from the patient for delivery to the lab. Onboarded patients will monitor their disease and symptoms through the digital health app provided by Aptar Digital Health and, when a blood test is required by the healthcare provider, samples will be collected with Tasso’s devices and sent for analysis.
“Our proprietary technology allows for easy, virtually-painless remote sample blood collection, creating an easier and more pleasant experience for patients and shifting how clinical research can be executed,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “We are dedicated to expanding access to patient-centric care, reducing barriers and supporting greater adoption of decentralized clinical trials. As part of that mission, we are pleased to collaborate with Aptar Digital Health, another leader working to transform healthcare, to offer a powerful combined solution for improving the clinical trial patient experience.”
Learn more about Tasso and their collaboration with Aptar Digital Health.
